MedTrace Logo

A Study of GC203 TIL in PDCA (RJ)

NCT06828328 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-12-23

No results posted yet for this study

Summary

This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

  • Pancreatic Cancer
  • Pancratic Ductal Adenocarcinoma
  • Treatment Side Effects
  • Tumor Infiltrating Lymphocytes

Interventions

BIOLOGICAL

GC203 TIL

the candidates will be assigned to GC203 TIL(gene-edited TIL) group

Sponsors & Collaborators

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-10
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06828328 on ClinicalTrials.gov